Inovio Pharma (INO) Stock Price, Quote & News

Company Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline inclu...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 440 4200

Website: www.inovio.com

Address:

660 West Germantown Pike, Suite 110, Plymouth Meeting, United States

Tracker7 Aug. 9 at 11:17 AM

$INO Just sent a news tip to the NY Times regarding their news article about RFK Jr. defunding mRNA. RFK Jr. is prioritizing antigen based vaccines instead of mRNA vaccines. Also mentioned to check out INOVIO Pharmaceuticals very likely, the very first DNA plasmid (antigen based) vaccine to be introduced in the USA, INO-3107 for throat cancer. It’s just a matter of time and DNA plasmid vaccines will be commonplace.

0 · Reply

Buqqets Aug. 9 at 6:20 AM

$INO anyone remember INO-4801 or are we just pretending that was never a thing?

0 · Reply

updownsides Aug. 9 at 4:06 AM

$INO Here is your typical Inovio leadership. Avtar Dhillon was significantly involved with Inovio. He served as the company's President and CEO from 2001 until June 2009. He remained on Inovio's board until 2019. However, in 2021, Dhillon was arrested in California on federal securities fraud charges. He pleaded guilty in 2022 and was sentenced to four months in prison, followed by one year of supervised release, and ordered to forfeit $1.5 million in illicit gains.

0 · Reply

Bunster Aug. 9 at 2:09 AM

$INO SO WHAT HAPPENED THE WEEK From August 2 2025 THRU today August 8 2025 IMO so if the monthly burn of CASH is 8.3 million DOLLARS And august has 31 days so tomato paste, primes math says we burned thru around 1.87 million dollars this week .ceo shea. prime would like to know what have we to show for the estimated 1.87 million dollars spent this week by inovio.? as u can see THIS a creative post, that u have never heard b4, brought to u by prime. so we would have to sell 1.35 million shares of our stock at a price of 1.40 to raise 1.87 million dollars.And girls thats without any warrants attached.And it seems, dr shea LOVES TO ATTACH WARRANTS TO HER OFFERINGS. PRIME

0 · Reply

BentleyT99 Aug. 9 at 1:56 AM

$INO INOVIO Should Partner With Big Pharma On This!!!!!!!

2 · Reply

55GaryCasssdy Aug. 8 at 10:49 PM

$INO Thank you L D for posting an article! Was beginning to get the shakes!

0 · Reply

Lookingdown Aug. 8 at 9:46 PM

$INO DNA Vaccines, an Innovative Vaccine Platform against COVID-19 August 8, 2025 https://link.springer.com/article/10.1007/s40588-025-00251-2

0 · Reply

Bunster Aug. 8 at 9:42 PM

$INO

0 · Reply

Bunster Aug. 8 at 9:37 PM

$INO buying that day pps was 4.15-4.61. 10 days later it was 2.32 TODAY 1.40.OUCH OUCH OUCH. KNOW YOUR PUMPER. I MEAN POSTER

0 · Reply

Bunster Aug. 8 at 9:35 PM

$INO 35 LIKES PPS THAT DAY LOD 9.60 HOD 10.92 pps now 1.40.POSTER hasnt stopped pumping since .IT LOOKS TO ME LIKE HEAVY HEAVY BAGS FOR OUR TOMATO..KNOW YOUR POSTER.Any sheep of tomato are losing a ton.

0 · Reply

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 7, 2025, 4:05 PM EDT - 4 weeks ago

INOVIO to Present at Upcoming Scientific Conference

Jul 3, 2025, 7:30 AM EDT - 5 weeks ago

INOVIO Announces Pricing of $25 Million Public Offering

Jul 2, 2025, 4:16 PM EDT - 5 weeks ago

INOVIO Announces Proposed Public Offering

Jul 1, 2025, 7:00 AM EDT - 5 weeks ago

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

May 13, 2025, 7:05 PM EDT - 3 months ago

Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 3 months ago

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 9, 2025, 7:37 PM EDT - 3 months ago

Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)

Apr 30, 2025, 8:05 AM EDT - 3 months ago

INOVIO to Present at Upcoming Scientific and Investor Conferences

Apr 29, 2025, 8:05 AM EDT - 3 months ago

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 9, 2025, 8:05 AM EDT - 4 months ago

INOVIO to Present at Upcoming Scientific Conferences

Mar 18, 2025, 8:48 PM EDT - 5 months ago

Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 5 months ago

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 13, 2025, 6:15 PM EDT - 5 months ago

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Mar 12, 2025, 12:55 PM EDT - 5 months ago

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Feb 12, 2025, 5:39 PM EST - 6 months ago

Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)

Feb 12, 2025, 8:00 AM EST - 6 months ago

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Feb 10, 2025, 8:05 AM EST - 6 months ago

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Jan 29, 2025, 4:14 PM EST - 6 months ago

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 8:04 AM EST - 7 months ago

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Jan 6, 2025, 7:19 AM EST - 7 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

OTLK RCKT

Dec 13, 2024, 2:10 PM EST - 8 months ago

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet

Dec 13, 2024, 7:00 AM EST - 8 months ago

INOVIO Announces Pricing of $30 Million Public Offering

Dec 3, 2024, 8:00 AM EST - 8 months ago

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Nov 29, 2024, 4:02 PM EST - 9 months ago

INOVIO Reports Inducement Grant Under Inducement Plan

Nov 15, 2024, 11:21 AM EST - 9 months ago

European And US Vaccine Stocks Are Under Pressure - Here's WHy

AZN BNTX GSK MRK SNY VALN

Nov 14, 2024, 7:53 PM EST - 9 months ago

Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:05 PM EST - 9 months ago

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 13, 2024, 8:00 AM EST - 9 months ago

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Nov 6, 2024, 8:00 AM EST - 9 months ago

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 21, 2024, 8:00 AM EDT - 10 months ago

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Oct 2, 2024, 4:15 PM EDT - 11 months ago

INOVIO Reports Inducement Grants Under Inducement Plan

Aug 9, 2024, 3:32 AM EDT - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Jul 25, 2024, 8:00 AM EDT - 1 year ago

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 11, 2024, 8:00 AM EDT - 1 year ago

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

Jul 2, 2024, 4:05 PM EDT - 1 year ago

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

Jul 1, 2024, 8:00 AM EDT - 1 year ago

INOVIO Added to Russell 2000® Index Effective July 1, 2024

Jun 4, 2024, 8:00 AM EDT - 1 year ago

INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.

May 20, 2024, 4:31 PM EDT - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)

May 15, 2024, 2:15 PM EDT - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)

May 14, 2024, 4:44 PM EDT - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)

May 13, 2024, 7:47 PM EDT - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 1 year ago

INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 29, 2024, 8:00 AM EDT - 1 year ago

INOVIO to Participate in Upcoming Investor Conferences in May

Apr 29, 2024, 8:00 AM EDT - 1 year ago

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 15, 2024, 6:39 PM EDT - 1 year ago

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Mar 26, 2024, 6:28 PM EDT - 1 year ago

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

Mar 6, 2024, 8:25 PM EST - 1 year ago

Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript

Tracker7 Aug. 9 at 11:17 AM

0 · Reply

Buqqets Aug. 9 at 6:20 AM

$INO anyone remember INO-4801 or are we just pretending that was never a thing?

0 · Reply

updownsides Aug. 9 at 4:06 AM

0 · Reply

Bunster Aug. 9 at 2:09 AM

0 · Reply

BentleyT99 Aug. 9 at 1:56 AM

$INO INOVIO Should Partner With Big Pharma On This!!!!!!!

2 · Reply

55GaryCasssdy Aug. 8 at 10:49 PM

$INO Thank you L D for posting an article! Was beginning to get the shakes!

0 · Reply

Lookingdown Aug. 8 at 9:46 PM

$INO DNA Vaccines, an Innovative Vaccine Platform against COVID-19 August 8, 2025 https://link.springer.com/article/10.1007/s40588-025-00251-2

0 · Reply

Bunster Aug. 8 at 9:42 PM

$INO

0 · Reply

Bunster Aug. 8 at 9:37 PM

$INO buying that day pps was 4.15-4.61. 10 days later it was 2.32 TODAY 1.40.OUCH OUCH OUCH. KNOW YOUR PUMPER. I MEAN POSTER

0 · Reply

Bunster Aug. 8 at 9:35 PM

0 · Reply

GermanBulle Aug. 8 at 8:47 PM

$INO I hate 2 interrupt your party, but it looks like a copy of the last pattern. IMO they drive it down 2 the next R/S. I do not hope, but I mean. Look at the daylight chart! Worse! M pattern is forming again. We have some who give a s***t about all these small pocket investors. Let them bleed out and make cash on the other hand. I hate that kind of a game. But reality will come over you after next ER. Sorry, like you. But …real world is bad

1 · Reply

rioe Aug. 8 at 7:56 PM

$INO The quieter it gets, the bigger the launch next week. Silence before the Boom! 🚀

1 · Reply

Bigda21 Aug. 8 at 4:39 PM

$INO the Inovio board has gathered below. The most pressing matter at hand is whether kies should be allowed the 20 piece bucket at kfc when historically he’s always gotten the 10 piece. He’s done such a great job on financings they have awarded him the 20 piece bucket! Way to go Peter!

1 · Reply

55GaryCasssdy Aug. 8 at 3:47 PM

$INO Singh is gone Veggie! Your due diligence is amazing

1 · Reply

tomonota Aug. 8 at 3:22 PM

$INO A little China revenue means 3100 is a 'go,' that news will be incendiary for a hot stock ready to burnish its mark.

1 · Reply

tomonota Aug. 8 at 3:18 PM

$INO I'm in 7,000 sh. this week before Earnings call- hoping for $13 this year based on our loyal analyst-friend Hartaj Singh's call at Oppenheimer. That's a 9-bagger from today's bargain price. This Co. is not likely to go south. I have seen a lot of small cos. in their position in my career- very few ever get liquidated, but remember these things take time before they work out. After that the founders are off to Disneyland. I am boarding that train too- the night train as James Brown said. Just gonna wait.

2 · Reply

55GaryCasssdy Aug. 8 at 2:34 PM

$INO Please Veggie and L D . It’s Friday! We need one of your pre weekend articles to get us through.

1 · Reply

Bigda21 Aug. 8 at 2:20 PM

$INO this is the hopium I love to see. Shorted more this morning. Shea is going to thumb her nose at all you inovians who see everything through the lens of turd colored glasses. I look forward to the 12th! Someone remind when Inovio has ever released good news on an earnings day (or ever really) lol #fakeinstitutionalinvestor #journeytozero #buttleyandrocketmanaregaylovers

0 · Reply

Dany_italy Aug. 8 at 2:15 PM

$INO A year has passed since this, we are getting closer, Europe, the US and then the whole world. This drug will pave the way for everything else in the pipeline. Here the cellectra is already CE marked, once we get the ok from the fda it will be easier https://synapse.patsnap.com/article/inovio-gets-advanced-therapy-certificate-from-ema-for-ino-3107

3 · Reply

Bigda21 Aug. 8 at 10:58 AM

$INO this -100% will be a reality sooner or later. I look forward to Mr institutional losing it all #scamcompany #pumper #anotherbuttleyalias

0 · Reply

James10067 Aug. 8 at 9:28 AM

$INO March 22, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its novel dMAb antibody and DNA vaccine targeting the chikungunya virus (CHIKV) provided 100% protection against a lethal virus challenge in mice. This breakthrough data was published in the latest issue of The Journal of Infectious Diseases in a paper,

0 · Reply

updownsides Aug. 8 at 7:04 AM

$INO Bigdazznutz21. Someone has the rocket ship ready for launch at your request. Just have to open the bay door.

0 · Reply

Market Cap	52.81M
Revenue (ttm)	220,000.00
Net Income (ttm)	-107.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48,750.00%
Debt to Equity Ratio	0.00

Volume	396,500
Avg Vol	1,871,512
Day's Range	N/A - N/A
Shares Out	36.67M
Stochastic %K	35%
Beta	1.38
Analysts	Strong Sell
Price Target	$7.14